{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:24:32Z","timestamp":1773213872742,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T00:00:00Z","timestamp":1465257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T00:00:00Z","timestamp":1465257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1038\/tpj.2016.44","type":"journal-article","created":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T10:03:50Z","timestamp":1465293830000},"page":"439-445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes"],"prefix":"10.1038","volume":"16","author":[{"given":"S","family":"Mas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Gass\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Lafuente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Bioque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Gonz\u00e0lez-Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M S","family":"Olmeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Corripio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Llerena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Saiz-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"PEPs GROUP","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisela","family":"Mezquida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Meseguer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique Garc\u00eda","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara","family":"Parellada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Alonso-Sol\u00eds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Grasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miryam","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica Martinez","family":"Cengotitabengoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fe","family":"Barcones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Arbej","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Sanjuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo J","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Balbuena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Man\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Torrent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Immaculada","family":"Baeza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena de la","family":"Serna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Auria","family":"Albacete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Paz","family":"Garc\u00eda-Portilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Bobes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arantzazu","family":"Zabala Rabad\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Segarra Echevarr\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Morales-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Rodriguez-Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Butjosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Usall Rodie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"Sarr\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Land\u00edn-Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Iba\u00f1ez Cuadrado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel J","family":"Cuesta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicent","family":"Balanz\u00e1-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,7]]},"reference":[{"key":"BFtpj201644_CR1","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951\u2013962.","journal-title":"Lancet"},{"key":"BFtpj201644_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/schbul\/sbq042","volume":"38","author":"C Rummel-Kluge","year":"2012","unstructured":"Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 2012; 38: 167\u2013177.","journal-title":"Schizophr Bull"},{"key":"BFtpj201644_CR3","doi-asserted-by":"publisher","first-page":"656370","DOI":"10.1155\/2014\/656370","volume":"2014","author":"N Divac","year":"2014","unstructured":"Divac N, Prostran M, Jakovcevski I, Cerovac N . Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int 2014; 2014: 656370.","journal-title":"Biomed Res Int"},{"key":"BFtpj201644_CR4","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/ajmg.b.30544","volume":"144B","author":"V Dolzan","year":"2007","unstructured":"Dolzan V, Plesnicar BK, Serretti A, Mandelli L, Zalar B, Koprivsek J et al. Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 809\u2013815.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"BFtpj201644_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.schres.2006.09.031","volume":"90","author":"A Lafuente","year":"2007","unstructured":"Lafuente A, Bernardo M, Mas S, Crescenti A, Aparici M, Gass\u00f3 P et al. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics. Schizophr Res 2007; 90: 115\u2013122.","journal-title":"Schizophr Res"},{"key":"BFtpj201644_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.psychres.2007.08.002","volume":"161","author":"A Lafuente","year":"2008","unstructured":"Lafuente A, Bernardo M, Mas S, Crescenti A, Aparici M, Gass\u00f3 P et al. Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins\/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders. Psychiatry Res 2008; 161: 131\u2013141.","journal-title":"Psychiatry Res"},{"key":"BFtpj201644_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/FPC.0b013e32800ffbb4","volume":"17","author":"L Greenbaum","year":"2007","unstructured":"Greenbaum L, Strous RD, Kanyas K, Merbl Y, Horowitz A, Karni O et al. Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication. Pharmacogenet Genomics 2007; 17: 519\u2013528.","journal-title":"Pharmacogenet Genomics"},{"key":"BFtpj201644_CR8","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/tpj.2009.26","volume":"9","author":"P Gass\u00f3","year":"2009","unstructured":"Gass\u00f3 P, Mas S, Bernardo M, Alvarez S, Parellada E, Lafuente A . A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. Pharmacogenomics J 2009; 9: 404\u2013410.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201644_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1177\/0269881112463469","volume":"27","author":"BR Lawford","year":"2013","unstructured":"Lawford BR, Barnes M, Swagell CD, Connor JP, Burton SC, Heslop K et al. DRD2\/ANKK1 Taq1A (rs 1800497 C>T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia. J Psychopharmacol 2013; 27: 343\u2013348.","journal-title":"J Psychopharmacol"},{"key":"BFtpj201644_CR10","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/JCP.0b013e31829abec9","volume":"33","author":"M Zivkovi\u0107","year":"2013","unstructured":"Zivkovi\u0107 M, Mihaljevi\u0107-Peles A, Bozina N, Saqud M, Nikolac-Perkovic M, Vuksan-Cusa B et al. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol. J Clin Psychopharmacol 2013; 33: 593\u2013599.","journal-title":"J Clin Psychopharmacol"},{"key":"BFtpj201644_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00228-006-0234-8","volume":"63","author":"C G\u00fczey","year":"2007","unstructured":"G\u00fczey C, Scordo MG, Spina E, Landsem VM, Spigset O . Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. Eur J Clin Pharmacol 2007; 63: 233\u2013241.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFtpj201644_CR12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00213-006-0622-x","volume":"190","author":"A Gunes","year":"2007","unstructured":"Gunes A, Scordo MG, Jaanson P, Dahl ML . Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psychopharmacol (Berl) 2007; 190: 479\u2013484.","journal-title":"Psychopharmacol (Berl)"},{"key":"BFtpj201644_CR13","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00228-007-0450-x","volume":"64","author":"A Gunes","year":"2008","unstructured":"Gunes A, Dahl ML, Spina E, Scordo MG . Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Eur J Clin Pharmacol 2008; 64: 477\u2013482.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFtpj201644_CR14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/YPG.0b013e3283328dcd","volume":"19","author":"I Al-Janabi","year":"2009","unstructured":"Al-Janabi I, Arranz MJ, Blakemore AI, Saiz PA, Susce MT, Glasser PE et al. Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. Psychiatr Genet 2009; 19: 305\u2013311.","journal-title":"Psychiatr Genet"},{"key":"BFtpj201644_CR15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1177\/0269881108091594","volume":"23","author":"B Wilffert","year":"2009","unstructured":"Wilffert B, Al Hadithy AF, Sing VJ, Matroos G, Hoek HW, van Os J et al. The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African\u2212Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX. J Psychopharmacol 2009; 23: 652\u2013659.","journal-title":"J Psychopharmacol"},{"key":"BFtpj201644_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.bbr.2011.01.025","volume":"219","author":"M Creed-Carson","year":"2011","unstructured":"Creed-Carson M, Oraha A, Nobrega JN . Effects of 5-HT(2\u2009A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats. Behav Brain Res 2011; 219: 273\u2013279.","journal-title":"Behav Brain Res"},{"key":"BFtpj201644_CR17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/FPC.0b013e32833efb18","volume":"21","author":"I Giegling","year":"2011","unstructured":"Giegling I, Drago A, Dol\u017ean V, Plesnicar BK, Sch\u00e4fer M, Hartmann AM et al. Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol. Pharmacogenet Genomics 2011; 21: 206\u2013216.","journal-title":"Pharmacogenet Genomics"},{"key":"BFtpj201644_CR18","doi-asserted-by":"publisher","first-page":"e44853","DOI":"10.1371\/journal.pone.0044853","volume":"7","author":"A Drago","year":"2012","unstructured":"Drago A, Giegling I, Sch\u00e4fer M, Hartmann AM, M\u00f6ller HJ, De Ronchi D et al. No association of a set of candidate genes on haloperidol side effects. PLoS One 2012; 7: e44853.","journal-title":"PLoS One"},{"key":"BFtpj201644_CR19","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.euroneuro.2012.08.013","volume":"23","author":"A Drago","year":"2013","unstructured":"Drago A, Giegling I, Sch\u00e4fer M, Hartmann AM, M\u00f6ller HJ, De Ronchi D et al. AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment. Eur Neuropsychopharmacol 2013; 23: 887\u2013894.","journal-title":"Eur Neuropsychopharmacol"},{"key":"BFtpj201644_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.psychres.2014.05.039","volume":"219","author":"P Tybura","year":"2014","unstructured":"Tybura P, Trze\u015bniowska-Druka\u0142a B, Bienkowski P, Beszlej A, Frydecka D, Mierzejewski P et al. Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine. Psychiatry Res 2014; 219: 261\u2013267.","journal-title":"Psychiatry Res"},{"key":"BFtpj201644_CR21","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/FPC.0b013e3283659a94","volume":"23","author":"B Almoguera","year":"2013","unstructured":"Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, Dorado P, Vaquero-Lorenzo C, Fernandez-Piqueras J et al. CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. Pharmacogenet Genomics 2013; 23: 627\u2013630.","journal-title":"Pharmacogenet Genomics"},{"key":"BFtpj201644_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.biopsych.2009.08.036","volume":"67","author":"K Aberg","year":"2010","unstructured":"Aberg K, Adkins DE, Buksz\u00e1r J, Webb BT, Caroff SN, Miller DD et al. Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 2010; 67: 279\u2013282.","journal-title":"Biol Psychiatry"},{"key":"BFtpj201644_CR23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00213-009-1627-z","volume":"206","author":"A Alkelai","year":"2009","unstructured":"Alkelai A, Greenbaum L, Rigbi A, Kanyas K, Lerer B . Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacol (Berl) 2009; 206: 491\u2013499.","journal-title":"Psychopharmacol (Berl)"},{"key":"BFtpj201644_CR24","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/ajmg.b.31245","volume":"156B","author":"A Drago","year":"2011","unstructured":"Drago A, Crisafulli C, Serretti A . The genetics of antipsychotic induced tremors: a genome-wide pathway analysis on the STEP-BD SCP sample. Am J Med Genet B Neuropsychiatr Genet 2011; 156B: 975\u2013986.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"BFtpj201644_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/0269881111424929","volume":"26","author":"PM Haddad","year":"2012","unstructured":"Haddad PM, Das A, Keyhani S, Chaudhry IB . Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons. J Psychopharmacol 2012; 26: 15\u201326.","journal-title":"J Psychopharmacol"},{"key":"BFtpj201644_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.rpsm.2012.11.001","volume":"6","author":"M Bernardo","year":"2013","unstructured":"Bernardo M, Bioque M, Parellada M, Saiz Ruiz J, Cuesta MJ, Llerena A et al. Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs). Rev Psiquiatr Salud Ment 2013; 6: 4\u201316.","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"BFtpj201644_CR27","unstructured":"American Psychiatric Association (Washington) DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, DC, USA, 1994."},{"key":"BFtpj201644_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","volume":"334","author":"O Lingjaerde","year":"1987","unstructured":"Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K . The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1\u2013100.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"BFtpj201644_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Angus JW . A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11\u201319.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"BFtpj201644_CR30","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","volume":"167","author":"DM Gardner","year":"2010","unstructured":"Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ . International consensus study of antipsychotic dosing. Am J Psychiatry 2010; 167: 686\u2013693.","journal-title":"Am J Psychiatry"},{"key":"BFtpj201644_CR31","first-page":"644","volume":"23","author":"JR Gonz\u00e1lez","year":"2007","unstructured":"Gonz\u00e1lez JR, Armengol L, Sol\u00e9 X, Guin\u00f3 E, Mercader JM, Estivill X et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics 2007; 23: 644\u2013645.","journal-title":"Bioinformatics"},{"key":"BFtpj201644_CR32","first-page":"229","volume":"2838","author":"A Jakulin","year":"2003","unstructured":"Jakulin A, Bratko I . Analyzing attribute interactions. Lect Notes Artif Intell 2003; 2838: 229\u2013240.","journal-title":"Lect Notes Artif Intell"},{"key":"BFtpj201644_CR33","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/01.jcp.0000203200.96205.34","volume":"26","author":"K Hedenmalm","year":"2006","unstructured":"Hedenmalm K, G\u00fczey C, Dahl ML, Yue QY, Spigset O . Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol 2006; 26: 192\u2013197.","journal-title":"J Clin Psychopharmacol"},{"key":"BFtpj201644_CR34","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/j.1745-7254.2006.00355.x","volume":"27","author":"SN Wu","year":"2006","unstructured":"Wu SN, Gao R, Xing QH, Li HF, Shen YF, Gu NF et al. Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sin 2006; 27: 966\u2013970.","journal-title":"Acta Pharmacol Sin"},{"key":"BFtpj201644_CR35","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/sj.mp.4001054","volume":"7","author":"R Kaiser","year":"2002","unstructured":"Kaiser R, Tremblay PB, Klufm\u00f6ller F, Roots I, Brockm\u00f6ller J . Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. Mol Psychiatry 2002; 7: 695\u2013705.","journal-title":"Mol Psychiatry"},{"key":"BFtpj201644_CR36","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1017\/S1461145706007152","volume":"10","author":"CC Zai","year":"2007","unstructured":"Zai CC, Hwang RW, De Luca V, M\u00fcller DJ, King N, Zai GC et al. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol 2007; 10: 639\u2013651.","journal-title":"Int J Neuropsychopharmacol"},{"key":"BFtpj201644_CR37","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/sj.mp.4002142","volume":"13","author":"PR Bakker","year":"2008","unstructured":"Bakker PR, van Harten PN, van Os J . Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008; 13: 544\u2013556.","journal-title":"Mol Psychiatry"},{"key":"BFtpj201644_CR38","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.clinthera.2012.06.010","volume":"34","author":"JJ Chen","year":"2012","unstructured":"Chen JJ, Ondo WG, Dashtipour K, Swope DM . Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther 2012; 34: 1487\u20131504.","journal-title":"Clin Ther"},{"key":"BFtpj201644_CR39","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/ajmg.b.30981","volume":"153B","author":"HT Tsai","year":"2010","unstructured":"Tsai HT, Caroff SN, Miller DD, McEvoy J, Lieberman J, North KE et al. A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 336\u2013340.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"BFtpj201644_CR40","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.jpsychires.2013.07.025","volume":"47","author":"CC Zai","year":"2013","unstructured":"Zai CC, Tiwari AK, Mazzoco M, de Luca V, M\u00fcller DJ, Shaikh SA et al. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. J Psychiatr Res 2013; 47: 1760\u20131765.","journal-title":"J Psychiatr Res"},{"key":"BFtpj201644_CR41","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/ajmg.b.30746","volume":"147B","author":"AF Al Hadithy","year":"2008","unstructured":"Al Hadithy AF, Wilffert B, Stewart RE, Looman NM, Bruggeman R, Brouwers JR et al. Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African\u2212Caribbean inpatients: differences in association with dopamine and serotonin receptors. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 890\u2013897.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"BFtpj201644_CR42","doi-asserted-by":"publisher","first-page":"e36561","DOI":"10.1371\/journal.pone.0036561","volume":"7","author":"PR Bakker","year":"2012","unstructured":"Bakker PR, Bakker E, Amin N, van Duijn CM, van Os J, van Harten PN . Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study. PLoS One 2012; 7: e36561.","journal-title":"PLoS One"},{"key":"BFtpj201644_CR43","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/JCP.0b013e3182902708","volume":"33","author":"W Knol","year":"2013","unstructured":"Knol W, van Marum RJ, Jansen PA, Strengman E, Al-Hadithy AF, Wilffert B et al. Genetic variation and the risk of haloperidol-related parkinsonism in elderly patients: a candidate gene approach. J Clin Psychopharmacol 2013; 33: 405\u2013410.","journal-title":"J Clin Psychopharmacol"},{"key":"BFtpj201644_CR44","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1017\/S1461145709991027","volume":"13","author":"G Laje","year":"2010","unstructured":"Laje G, Cannon DM, Allen AS, Klaver JM, Peck SA, Liu X et al. Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB. Int J Neuropsychopharmacol 2010; 13: 715\u2013724.","journal-title":"Int J Neuropsychopharmacol"},{"key":"BFtpj201644_CR45","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s00335-011-9385-8","volume":"23","author":"JJ Crowley","year":"2012","unstructured":"Crowley JJ, Kim Y, Szatkiewicz JP, Pratt AL, Quackenbush CR, Adkins DE et al. Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice. Mamm Genome 2012; 23: 322\u2013335.","journal-title":"Mamm Genome"},{"key":"BFtpj201644_CR46","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1038\/tp.2011.66","volume":"2","author":"SA Ivanova","year":"2012","unstructured":"Ivanova SA, Loonen AJ, Pechlivanoglou P, Freidin MB, Al-Hadithy AF, Rudikov EV et al. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia. Transl Psychiatry 2012; 2: e67.","journal-title":"Transl Psychiatry"},{"key":"BFtpj201644_CR47","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/npp.2009.220","volume":"35","author":"A Syu","year":"2010","unstructured":"Syu A, Ishiguro H, Inada T, Horiuchi Y, Tanaka S, Ishikawa M et al. Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia. Neuropsychopharmacol 2010; 35: 1155\u20131164.","journal-title":"Neuropsychopharmacol"},{"key":"BFtpj201644_CR48","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/tpj.2011.32","volume":"12","author":"L Greenbaum","year":"2012","unstructured":"Greenbaum L, Alkelai A, Zozulinsky P, Kohn Y, Lerer B . Support for association of HSPG2 with tardive dyskinesia in Caucasian populations. Pharmacogenomics J 2012; 12: 513\u2013520.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201644_CR49","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.2217\/pgs.12.159","volume":"13","author":"S Mas","year":"2012","unstructured":"Mas S, Llerena A, Sa\u00edz J, Bernardo M, Lafuente A . Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. Pharmacogenomics 2012; 13: 1773\u20131782.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201644_CR50","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/tpj.2010.91","volume":"12","author":"S Mas","year":"2012","unstructured":"Mas S, Gass\u00f2 P, Alvarez S, Parellada E, Bernardo M, Lafuente A . Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics J 2012; 12: 255\u2013259.","journal-title":"Pharmacogenomics J"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj201644.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201644","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201644.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T11:42:27Z","timestamp":1718624547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,7]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["BFtpj201644"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2016.44","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,7]]},"assertion":[{"value":"30 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AA has received a trainee research staff grant awarded by the University of Barcelona (APIF-UB grants). AB has received grants from the Spanish Ministry of Science and Innovation (FIS). AL has received grants from the Spanish Ministry of Science and Innovation (FIS). AM has received financial support to attend meetings, travel support and served as a speaker from Otsuka and Janssen-Cilag. EV has received grants and served as consultant, advisor or CME speaker for the following entities: AstraZeneca, Bristol-Myers Squibb, Ferrari, Forest Research Institute, Gideon Richter, GlaxoSmithKline, Janssen, Lundbeck, Otsuka, Pfizer, Roche, Snafu-Aventis, Servier, Shire, Sunovion, Takeda, the Brain and Behaviour Foundation, the Spanish Ministry of Science and Innovation (CIBERSAM), the Seventh European Framework Programme (ENBREC) and the Stanley Medical Research Institute. FC has received financial support to attend meetings, travel support and served as advisor or speaker for the following entities: Lilly, Janssen-Cilag, Lundbeck, Otsuka, the Spanish Ministry of Science and Innovation (CIBERSAM) and the Ministry of Science (Carlos III Institute). IB has received grants from CIBERSAM, Fundaci\u00f3n Alicia Koplowitz and Institute de Salad Carlos III, and has received honoraria as a speaker for Janssen, as well as support from Otsuka for attending some conferences. MB has been a consultant for, received grant\/research support and honoraria from, and been on the speakers\/advisory board of ABBiotics, Adamed, Almirall, AMGEN, Eli Lilly, Ferrari, Forum Pharmaceuticals, Gideon, Hersill, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Roche and Servier, and has obtained research funding from the Spanish Ministry of Health, the Spanish Ministry of Science and Education, the Spanish Ministry of Economy and Competitiveness, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental (CIBERSAM), by the Government of Catalonia, Secretaria d\u2019Universitats i Recerca del Departament d\u2019Economia i Coneixement, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS) and the 7th Framework Program of the European Union. MB has been a consultant for, received grant\/research support and honoraria from, and been on the speakers\/advisory board of Adamed, Ferrer, Janssen-Cilag, Lundbeck, Otsuka and Pfizer. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}